WO2007113365B1 - Uso de péptidos derivados de la lactoferrina en la preparación de medicamentos inhibidores de la enzima conversora de angiotensina i - Google Patents
Uso de péptidos derivados de la lactoferrina en la preparación de medicamentos inhibidores de la enzima conversora de angiotensina iInfo
- Publication number
- WO2007113365B1 WO2007113365B1 PCT/ES2007/070067 ES2007070067W WO2007113365B1 WO 2007113365 B1 WO2007113365 B1 WO 2007113365B1 ES 2007070067 W ES2007070067 W ES 2007070067W WO 2007113365 B1 WO2007113365 B1 WO 2007113365B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- converting enzyme
- angiotensin
- peptides
- seq
- pharmaceutical composition
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract 10
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract 5
- 102400000344 Angiotensin-1 Human genes 0.000 title abstract 2
- 101800000734 Angiotensin-1 Proteins 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 title abstract 2
- 102000004190 Enzymes Human genes 0.000 title 1
- 108090000790 Enzymes Proteins 0.000 title 1
- 102000010445 Lactoferrin Human genes 0.000 claims abstract 3
- 108010063045 Lactoferrin Proteins 0.000 claims abstract 3
- 229940078795 lactoferrin Drugs 0.000 claims abstract 3
- 235000021242 lactoferrin Nutrition 0.000 claims abstract 3
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 206010020772 Hypertension Diseases 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 102000057297 Pepsin A Human genes 0.000 claims 1
- 108090000284 Pepsin A Proteins 0.000 claims 1
- 235000015872 dietary supplement Nutrition 0.000 claims 1
- 239000013538 functional additive Substances 0.000 claims 1
- 235000013376 functional food Nutrition 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 229940111202 pepsin Drugs 0.000 claims 1
- 239000000047 product Substances 0.000 claims 1
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 abstract 3
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 abstract 3
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 abstract 3
- 230000000975 bioactive effect Effects 0.000 abstract 2
- 101000798100 Bos taurus Lactotransferrin Proteins 0.000 abstract 1
- 241000283973 Oryctolagus cuniculus Species 0.000 abstract 1
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 229940072440 bovine lactoferrin Drugs 0.000 abstract 1
- 210000001715 carotid artery Anatomy 0.000 abstract 1
- 230000008602 contraction Effects 0.000 abstract 1
- 235000013365 dairy product Nutrition 0.000 abstract 1
- 235000013305 food Nutrition 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000002417 nutraceutical Substances 0.000 abstract 1
- 235000021436 nutraceutical agent Nutrition 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Zoology (AREA)
- Peptides Or Proteins (AREA)
Abstract
La invención consiste en la utilización de productos bioactivos derivados de la proteínas láctea lactoferrina y el hidrolizado de lactoferrina que contiene dichos productos. Se trata de un péptido de quince residuos de aminoácidos (llamado LfcinB 17-31), y de otro que es una versión reducida del mismo (llamado LfcinB20-25), derivados de la lactoferrina bovina como inhibidores efectivos de la enzima conversora de la angiotensina (ECA). Los péptidos objeto de la patente se pueden obtener químicamente, enzimáticamente o biotecnológicamente y dan lugar a péptidos con actividad inhibidora de la enzima convertidora de la angiotensina in vitro y/o ex vivo, medida como la disminución de la contracción de arterias carótidas de conejo inducida por exposición a angiotensina I. Estos productos nutracéuticos, ya sea como péptido biactivos, son tanto útiles para la industria alimentaria como para la farmacéutica.
Claims
1.- Uso de un péptido que comprende la secuencia de aminoácidos SEQ ID NO 2 en la preparación de una composición farmacéutica para el tratamiento de la 5 hipertensión.
2. - Uso del péptido según la reivindicación 1 caracterizado por la secuencia de aminoácidos SEQ ID NO i .
3. - Uso de un péptido según la reivindicación 1 caracterizado porgue comprende/ al menos, la SEQ ID N02.
10 4.- Uso de un péptido según la reivindicación 1 caracterizado porque comprende la SEQ ID N02 y la SEQ ID NOl.
5.- Uso de un hidrolizado de lactoferrina con pepsina que comprende los péptidos de SEQ ID NO 1 y SEQ ID NO 2 en la 15 preparación de una composición farmacéutica para el tratamiento de la hipertensión.
6.- Composición farmacéutica útil para el tratamiento de la hipertensión caracterizada porque se elabora según las reivindicaciones 1 a la 5. 20
7. - Composición farmacéutica según la reivindicación 6 caracterizada porque dicha composición farmacéutica se formula como un aditivo, ingrediente o suplemento alimentario funcional.
8.- Producto alimentario funcional caracterizado porque 25 comprende una composición farmacéutica según la reivindicación 7.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200600881A ES2321358B1 (es) | 2006-04-05 | 2006-04-05 | Uso de peptidos derivados de la lactoferrina para preparar formulaciones inhibidoras de la enzima conversora de angiotensina i. |
| ESP200600881 | 2006-04-05 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2007113365A1 WO2007113365A1 (es) | 2007-10-11 |
| WO2007113365B1 true WO2007113365B1 (es) | 2007-11-29 |
Family
ID=38563144
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/ES2007/070067 WO2007113365A1 (es) | 2006-04-05 | 2007-04-02 | Uso de péptidos derivados de la lactoferrina en la preparación de medicamentos inhibidores de la enzima conversora de angiotensina i |
Country Status (2)
| Country | Link |
|---|---|
| ES (2) | ES2321358B1 (es) |
| WO (1) | WO2007113365A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2388094B1 (es) * | 2011-02-28 | 2013-09-13 | Consejo Superior Investigacion | Fraccion de bajo peso molecular de un hidrolizado de lactoferrina para el tratamiento de la hipertension. |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0503939B1 (en) * | 1991-03-13 | 1997-06-18 | Morinaga Milk Industry Co., Ltd. | Antimicrobial peptide and antimicrobial agent |
| GB9818938D0 (en) * | 1998-08-28 | 1998-10-21 | Alpharma As | Bioactive peptides |
-
2006
- 2006-04-05 ES ES200600881A patent/ES2321358B1/es not_active Expired - Fee Related
-
2007
- 2007-03-15 ES ES200700684A patent/ES2328435B1/es not_active Expired - Fee Related
- 2007-04-02 WO PCT/ES2007/070067 patent/WO2007113365A1/es active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| ES2328435B1 (es) | 2010-10-13 |
| WO2007113365A1 (es) | 2007-10-11 |
| ES2321358A1 (es) | 2009-06-04 |
| ES2321358B1 (es) | 2010-03-05 |
| ES2328435A1 (es) | 2009-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hayes et al. | Boarfish protein recovery using the pH-shift process and generation of protein hydrolysates with ACE-I and antihypertensive bioactivities in spontaneously hypertensive rats | |
| Yang et al. | Peptide with angiotensin I-converting enzyme inhibitory activity from hydrolyzed corn gluten meal | |
| Aluko | Structure and function of plant protein-derived antihypertensive peptides | |
| JP5002603B2 (ja) | 新規なペプチド及びこれの用途 | |
| EP2495250A3 (en) | Bioactive peptides identified in enzymatic hydrolyzates of milk caseins and method of obtaining same | |
| Marambe et al. | Release of angiotensin I-converting enzyme inhibitory peptides from flaxseed (Linum usitatissimum L.) protein under simulated gastrointestinal digestion | |
| NO20060994L (no) | Biologisk ikke-nedbrytbart peptid, angiotensinomdannende enzyminhibitor, medikament og funksjonell fode | |
| EP2455462A3 (en) | Lipase variants for pharmaceutical use | |
| CO2022006972A2 (es) | Composiciones que comprenden cepas bacterianas para uso en el aumento de la biodisponibilidad de aminoácidos derivados de proteínas | |
| WO2009007714A3 (en) | Human pancreatic polypeptide (hpp) analogues and their effects on feeding behaviour | |
| WO2009011544A3 (en) | Insulinotropic peptide derivative wherein its n-terminal amino acid is modified | |
| EA201171490A1 (ru) | Производные сывороточного амилоида р и их получение и применение | |
| WO2005124341A3 (en) | Stable isotope labeled polypeptide standards for protein quantitation | |
| JP2010520274A (ja) | ホエーからのａｃｅ抑制ペプチド及び同物を提供する方法 | |
| WO2011028195A3 (en) | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides | |
| WO2010130830A3 (en) | Anti-sclerostin vhh and their use for treating bone diseases | |
| WO2009064366A3 (en) | Methods and compositions for protein labeling using lipoic acid ligases | |
| Mas-Capdevila et al. | Long-term administration of protein hydrolysate from chicken feet induces antihypertensive effect and confers vasoprotective pattern in diet-induced hypertensive rats | |
| Gong et al. | Investigation of nutritional and functional effects of rice bran protein hydrolysates by using Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines: A review | |
| ATE449790T1 (de) | Rekombinante gelatinepartikel für die zelladhäsion | |
| DK1661913T3 (da) | Bioaktive peptider udledt fra æggehvideprotein gennem enzymatisk hydrolyse | |
| WO2008047370A3 (en) | Compositions and methods for inducing angiogenesis | |
| NZ594481A (en) | Truncated cystine-knot proteins | |
| ATE493999T1 (de) | Nahrungsmittel enthaltend dipeptide mit blutdrucksenkenden eigenschaften. | |
| WO2007113365B1 (es) | Uso de péptidos derivados de la lactoferrina en la preparación de medicamentos inhibidores de la enzima conversora de angiotensina i |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07730506 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 07730506 Country of ref document: EP Kind code of ref document: A1 |